Login / Signup

The effect of basal-bolus therapy varies with baseline 1,5-anhydroglucitol level in people with Type 2 diabetes: a post hoc analysis.

Simon R HellerKeith BoweringP RaskinA LieblK BuchholtzA Gorst-RasmussenT R Pieber
Published in: Diabetic medicine : a journal of the British Diabetic Association (2018)
This analysis indicates that people with Type 2 diabetes with low 1,5-anhydroglucitol have an added treatment benefit with basal-bolus therapy compared with people with higher 1,5-anhydroglucitol. Further research is needed to clarify any clinical utility of these findings. Clinical Trials Registry No: NCT01850615.
Keyphrases
  • clinical trial
  • stem cells
  • randomized controlled trial
  • bone marrow
  • combination therapy
  • open label
  • cell therapy
  • smoking cessation